Spend :01 of your time each Monday morning as Twelve:01 delivers timely tools, trends, strategies, and/or compliance insights for the CME/CE enterprise.
The ACCME’s recently released guidance on the responsible use of AI in accredited continuing education makes clear that innovation does not diminish accountability – it heightens it. While AI offers opportunities to scale and personalize learning, providers remain fully responsible for the accuracy, independence, and integrity of all learner-facing content, including AI-generated outputs. The guidance emphasizes rigorous pre-deployment validation, ongoing monitoring, and active clinical oversight, alongside strict separation from promotional influence. Transparency with learners and clear guardrails around AI functionality are essential, not optional. Failure to meet these expectations could place an organization’s accreditation at immediate risk, reinforcing that AI governance is now a core compliance function for accredited CME/CE providers.
For accredited organizations designing nursing continuing professional development (NCPD) activities, understanding ANCC pharmacotherapeutic credit criteria is essential for compliance and learner value. To qualify, content must explicitly focus on pharmacotherapeutics, though presenters are not required to be nurses, as long as they demonstrate subject matter expertise in pharmacology. Accredited providers should clearly delineate the number of pharmacotherapeutic contact hours during activity planning and include in program materials, so learners are aware. This creates opportunities for CME/CE providers to more intentionally design and document education around drug-specific information, safe prescribing and administration practices, and evolving regulatory guidance, ultimately supporting nurse learners in maintaining certification and improving medication-related outcomes.
Just this month the Council for Medical Specialty Societies (CMSS) revised its updates to its Code for Interactions with Companies previously released in September of 2025. Of particular note, recent revisions remove CMSS’ detailed guidance on clinical, non-accredited education – what had been Section 5.2. In the 2025 version of the Code, Section 5.2 outlined specific expectations for non-accredited education (e.g., content control, scientific rigor, and financial disclosure). In the 2026 update, non-accredited activities are no longer explicitly governed within Section 5, which is now focused exclusively on accredited continuing education (what CMSS calls ACE). Independence and transparency remain paramount, but how this is achieved when it comes to non-accredited education is up to individual societies.
